Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp8 | Acromegaly | ECE2018

ACRONIS, a European observational study in patients with uncontrolled acromegaly who are being treated with long acting pasireotide: first interim analysis

Schofl Christof , Colao Annamaria , Neggers SJCMM , Feldt-Rasmussen Ulla , Moreno Eva Maria Venegas , Enderle Gesine , Mesenska Daniela , Andry Philippe , Tabarin Antoine

Acromegaly is a morbid condition mainly caused by overproduction of growth-hormone (GH) from a pituitary adenoma leading to excessive growth. Normalisation of insulin-like growth factor-1 (IGF1) is an important goal for the treatment of acromegaly. The second-generation somatostatin analog (SSA) long acting pasireotide (la-PAS) has recently been introduced for the management of patients uncontrolled by first-generation SSA. The ACRONIS study (CSOM230CIC05) will provide real-wo...